<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319006</url>
  </required_header>
  <id_info>
    <org_study_id>114703</org_study_id>
    <nct_id>NCT01319006</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study for GSK1278863A</brief_title>
  <official_title>A Randomized, Open-label, 3-period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of Single Oral 100mg Doses of GSK1278863A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, 3-period crossover study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, 3-period crossover study in healthy subjects. The primary objective&#xD;
      of this study is to determine the relative bioavailability of GSK1278863A after single oral&#xD;
      doses of 100mg GSK1278863A tablets with particle sizes of 13, 29, or 41 micrometers (um) in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2011</start_date>
  <completion_date type="Actual">April 18, 2011</completion_date>
  <primary_completion_date type="Actual">April 18, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma concentration-time curve (AUC (0-inf)) and maximum plasma concentration (Cmax) of GSK1278863A.</measure>
    <time_frame>pre-dose to 24 hours post-dose</time_frame>
    <description>To determine the relative bioavailability of GSK1278863A after single oral doses of 100 mg GSK1278863A tablets with particle sizes of 13, 29 and 41um in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, AUC (0-t), AUC(0-infinite), tmax, and t1/2 (as data permit) of GSK1278863A metabolites.</measure>
    <time_frame>pre-dose to 24 hours post-dose</time_frame>
    <description>To determine the relative exposures of metabolites of GSK1278863A after single oral doses of 100 mg GSK1278863A tablets with particle sizes of 13, 29 and 41um in healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of investigational product as assessed by clinical monitoring of vital signs (blood pressure, pulse rate), ECGs, and laboratory data, as well as reporting of adverse events.</measure>
    <time_frame>Duration of subject study participation</time_frame>
    <description>To assess the safety and tolerability of GSK1278863A after single oral doses of 100 mg GSK1278863A tablets with particle sizes of 13, 29 and 41um in healthy subjects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>GSK1278863A 100mg (X90=13um)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863A 100mg (x90=29Um)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863 100mg (X90=41um)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863A</intervention_name>
    <description>100mg (x90=13um), oral tablet, single-dose with 7 day wash-out</description>
    <arm_group_label>GSK1278863 100mg (X90=41um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (X90=13um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (x90=29Um)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863A</intervention_name>
    <description>100mg (x90=29um), oral tablet, single-dose with 7 day wash-out</description>
    <arm_group_label>GSK1278863 100mg (X90=41um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (X90=13um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (x90=29Um)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863A</intervention_name>
    <description>100mg (x90=41um), oral tablet, single-dose with 7 day wash-out</description>
    <arm_group_label>GSK1278863 100mg (X90=41um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (X90=13um)</arm_group_label>
    <arm_group_label>GSK1278863A 100mg (x90=29Um)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin &lt;= 1.5xULN (isolated bilirubin &gt;1.5xULN&#xD;
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including: medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use&#xD;
             contraception methods&#xD;
&#xD;
          -  Body weight &gt;=50kg and BMI within the range 19 to 29.9kg/m2 (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.&#xD;
&#xD;
          -  Subjects must have a normal resting blood pressure, after having rested quietly in a&#xD;
             supine position for at least 15 minutes, defined as: &gt;=100mm Hg systolic/60mm Hg&#xD;
             diastolic and &lt;=140mm Hg systolic/90mm Hg diastolic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality identified on the screening medical assessment,&#xD;
             laboratory examination, or ECG (12 lead) judged by the Investigator and /or medical&#xD;
             monitor to potentially introduce additional risk factors and/or interfere with the&#xD;
             study procedures.&#xD;
&#xD;
          -  Significant cardiac, pulmonary, metabolic, renal, hepatic, neurological, psychiatric,&#xD;
             or gastrointestinal conditions that in the opinion of the investigator and/or GSK&#xD;
             medical monitor, places the subject at an unacceptable risk as participant in this&#xD;
             trial.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  CPK above the normal range.&#xD;
&#xD;
          -  Calculated creatinine clearance: &lt;80mL/min.&#xD;
&#xD;
          -  Subjects with a pre-exisisting condition interfering with normal gastrointestinal&#xD;
             anatomy or motility, and/or hepatic function-that could interfere with the absorption,&#xD;
             metabolism, and/or excretion of the study drugs.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of &gt;21 drinks for males or &gt;14 drinks for females. One drink is&#xD;
             equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine&#xD;
             or 1.5 ounces (45 ml) of 80 proof distilled spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  History of peptic ulcer disease or of chronic rectal bleeding.&#xD;
&#xD;
          -  History of malignancy. Non-melanoma skin cancer that has been definitively removed is&#xD;
             allowed.&#xD;
&#xD;
          -  Subjects with a baseline medical history of proliferative diabetic retinopathy,&#xD;
             preproliferative diabetic retinopathy, or wet age-related macular degeneration (AMD).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is longer) prior to the first dose of investigational product.&#xD;
&#xD;
          -  History of sensitivity to any of the investigational products, or components thereof&#xD;
             or a history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History or sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking. History or regular use of tobacco or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of &gt;3 servings per day of red wine, grapefruit (juice), blood orange&#xD;
             (juice), star fruit, onions, kale, broccoli, green beans, or apples from 7 days prior&#xD;
             to the first dose of investigational product, unless in the opinion of the&#xD;
             Investigator and GSK Medical Monitor this will not interfere with the study procedures&#xD;
             and compromise subject safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relative bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114703</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

